You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
部分醫藥股低位見承接 藥明系、開拓及金斯瑞反彈5%-9%
國家藥監局上週五發布提高抗腫瘤臨牀研發標準令研發成本增加,但大摩及中金均認爲新規下龍頭公司長期將受益。醫藥相關板塊繼昨天全面下挫後,今天部分低位見承接反彈,藍籌藥明生物(02269.HK)今早低開5%報120元(守穩百天線119.82元及昨天盤中所創逾兩週低位116.5元),即掉頭扭五連跌兼重越20天線(132.15元),最高見135元,現造133.4元,倒升5.5%。藥明康德(02359.HK)扭轉由上市高位三連跌反覆重越20天線(171.8元),高低見176.2元/164.3元,現造176.1元,回升5.6%,旗下藥明巨諾-B(02126.HK)承過去五連跌勢,今早股價低開報21.1元獲承接,掉頭高見23.2元,現造22.5元,反彈5.4%。

金斯瑞生物(01548.HK)繼昨天由收市紀錄高位回吐逾4%後,今早回升9.2%報35.7元即市高位,股價重越20天及10天線(33.4元及34.5元)。開拓藥業-B(09939.HK)重越10天線(60.5元),今早高低見62.5元/58元,現造61.9元,回升4.8%。

康龍化成(03759.HK)三連跌力守50天線(179.6元)後,今早股價反覆回升3.9%,報188.2元。泰格醫藥(03347.HK)由約五個月高位連吐兩天後,今早高低見168.5元/159.1元,現造167.6元,反覆回升3%。此外,海吉亞醫療(06078.HK)扭五連跌,今早股價反覆重越20天線(95.75),高低見96.4元/89.8元,現造95.85元,反覆回升4.8%。康健國際醫療(03886.HK)高見0.68元(剛爲牛熊線),現造0.64元,回升6.7%。

國家藥品監督管理局藥品審評中心上週五發布徵求《以臨牀價值爲導向的抗腫瘤藥物臨牀研發指導原則》意見的通知指,藥物進行臨牀對照試驗時應儘量爲受試者提供臨牀實踐中最佳治療方式及藥物、新藥研發應以爲患者提供更優治療選擇爲最高目標。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account